Tilray Inc (TLRY)
$19.81 1.12 (5.35%)
19:59 EST TLRY Stock Quote Delayed 15 Minutes
Previous Close $19.81
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 2.71M
Day's Range 19.50 - 20.84
52-Week Range 19.50 - 120.40
Dividend & Yield N/A (N/A)
TLRY Stock Predictions, Articles, and Tilray Inc News
- From InvestorPlace
- From the Web
Walmart and Cisco stock beat on earnings, but fell on Thursday. Here's what happened in the stock market today.
Investors justifiably have low expectations for TLRY stock ahead of quarterly earnings. Here's the outlook for Tilray through the end of 2019.
Tilray stock is hovering near its IPO level. The cannabis bubble has burst, but that doesn't mean TLRY should be treated like a penny stock.
Tilray stock has been stuck in a multi-quarter decline, and the fundamentals imply that the slide of TLRY stock may not be over.
Thanks to favorable public sentiment and political tailwinds, the list of marijuana stocks to buy is both extensive and diverse.
Throughout 2019, Tilray stock and its cannabis peers have hemorrhaged market value. But a development within the sphere of cancer research has brought legitimacy to both TLRY and the broader industry.
Tilray's cash burn and regulatory issues make Tilray stock unattractive. Investors shouldn't buy TLRY stock yet.
If Tilray stock breaks the $17 level, the IPO price will become a resistance level. Investors should also expect short selling there.
Tilray stock probably has further to fall since TLRY must overcome further funding obstacles before it can become a profitable company.
Tilray stock tumbles as investors demand profitability. Tilray, like other cannabis stocks, is stuck in a death spiral as long as the copmany can't produce profits.
Tilray stock keeps falling and now is nearing its IPO price. Trading in TLRY stock shows how much faith investors have lost in pot stocks.
It’s been absolutely grueling for Tilray stock. It seems like nothing can help shares. But interestingly enough, this may be setting up a good entry point for TLRY.
Revised earnings guidance for Hexo spooked the market and hit cannabis stocks, with Tilray stock closing down 13.5% on Thursday.
If understood and used correctly, technical analysis of marijuana stocks can allow you to identify important levels and trends -- and profit.
Tilray stock's 52-week high is just under $179. On Friday, Oct. 4, the shares barely closed above $24. The outlook for Tilray and some of its marijuana rivals will improve at some point. Knowing when that point will arrive, well, that's a different ballgame. Over the near-term, things are problematic for Tilray stock because losses are accelerating. Over the past month, the shares are lower by 25% and the loss of the past quarter is almost double that.
Opportunities abound for Tilray stock but the cannabis infrastructure still needs to be built out, along with more favorable legalization momentum. For now, TLRY is interesting, but it will require patience from investors.
By Thomas Niel
The company has several catalysts in play, but nothing unique compared to what other cannabis companies are doing. I remain on the fence with pot stocks in general. But if I were entering a position today, I would choose something like Hexo or Aphria to place my bet on the legalized marijuana story. I suggest you do the same. Look elsewhere for a pot play, but steer clear of TLRY stock.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!